RecruitingPhase 4NCT07187583
Tapering of Biologics in Chronic Rhinosinusitis With Nasal Polyps
Sponsor
Rigshospitalet, Denmark
Enrollment
135 participants
Start Date
Jun 5, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to investigate the feasibility of extending the dosing intervals of biological therapies while maintaining optimal treatment effects in chronic rhinosinusitis with nasal polyps (CRSwNP).
Eligibility
Min Age: 18 Years
Inclusion Criteria12
- ≥18 years of age.
- Currently receiving treatment with either dupilumab (300 mg) or mepolizumab (100 mg) every four weeks.
- Having received the biologic at unchanged dosing interval for at least three months.
- For at least one year during treatment with biologics, the patients' CRSwNP must be categorized as "partly controlled" as defined by presence of 1-2 of the following seven items (also available in EPOS 2020 table in protocol):
- Nasal blockage: present on most days of the week
- Rhinorrhoea/postnasal drip: mucopurulent on most days of the week
- Facial pain/pressure: present on most days of the week
- Sense of smell: impaired
- Sleep disturbance or fatigue: present
- Nasal endoscopy: diseased mucosa
- Rescue treatment (systemic corticosteroids, ESS, antibiotics): need of 1 course of rescue treatment
- of which 1-5 will be scored by the patient using VAS (0-10) and noted above 5.
Exclusion Criteria9
- Patients with excellent response to biologics (0 of the above-mentioned 7 items for partly controlled disease)
- Patients with no or limited response to biologics (>2 of the above-mentioned 7 items for partly controlled disease)
- Patients with a cancer diagnosis deemed by the investigator to preclude participation in the trial
- Patients who, because of language barriers, are not able to understand Danish written information and, thus, are not able to answer questionnaires
- Patients who currently receive biologics for any other disease (asthma not included)
- Patients who are not able to give informed consent (i.e., patients who are permanently incapable)
- Patients who are not eligible because of the investigator's judgement
- Patients who experience pregnancy during the study will be excluded after an unscheduled visit - active IVF treatment (please see below)
- Unwillingness to follow the study procedure
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGincreased dosing interval of biological therapy
Increasing dosing interval of biological therapy for CRSwNP from every 4 weeks to every 6 weeks and if continued satisfactory response then to every 8 weeks.
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07187583
Related Trials
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study
NCT0691490824 locations
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347121 locations
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360113 locations
A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients
NCT0744673810 locations
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
NCT0670681745 locations